Last reviewed · How we verify
Saluron (HYDROFLUMETHIAZIDE)
Saluron (HYDROFLUMETHIAZIDE) is a thiazide diuretic small molecule drug that targets the solute carrier family 12 member 3. It was originally developed by SHIRE LLC and is currently owned by Shire LLC. FDA approved in 1959, it is used to treat edema and hypertensive disorders. As an off-patent medication, it is available as a generic from multiple manufacturers. Key safety considerations include its short half-life of 5.2 hours and moderate bioavailability of 50%.
At a glance
| Generic name | HYDROFLUMETHIAZIDE |
|---|---|
| Sponsor | Shire Llc |
| Drug class | Thiazide Diuretic |
| Target | Solute carrier family 12 member 3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1959 |
Approved indications
- Edema
- Hypertensive disorder
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Dizziness
- Headache
- Rash
- Weakness
- Anorexia
- Gastric irritation
- Cramping
- Vertigo
Serious adverse events
- Aplastic anemia
- Agranulocytosis
- Pancreatitis
- Jaundice (intrahepatic cholestatic)
- Necrotizing angiitis (vasculitis)
- Leukopenia
- Thrombocytopenia
- Purpura
- Glycosuria
- Restlessness
Drug interactions
- lithium
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saluron CI brief — competitive landscape report
- Saluron updates RSS · CI watch RSS
- Shire Llc portfolio CI